Global R&D Pipeline
My Favorite
Hot Targets:
KLK5
Back
Total number of drugs
14
Phase II and later clinical stages
7.1%
Involving companies
13
Main therapeutic areas
Other Diseases
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TRIV-509 | TRIV-509 | Monoclonal antibody | Immune System Diseases Congenital Disorders Respiratory Diseases Skin and Musculoskeletal Diseases | KLK5 inhibitors KLK7 inhibitors | Triveni Bio, Inc. | Triveni Bio, Inc. | Phase 2 | - | - | - | - | - | - | - | - | - | TRIV-509 | - | - | detail > | |
| BCX-17725 | BCX-17725 | Fusion protein | Congenital Disorders Skin and Musculoskeletal Diseases Other Diseases | KLK5 inhibitors | BioCryst Pharmaceuticals, Inc. | BioCryst Pharmaceuticals, Inc. | Phase 1 | - | - | - | - | - | - | - | - | - | BCX-17725 | - | - | detail > | |
| DS-2325 | DS-2325 | Gene therapy | Congenital Disorders Skin and Musculoskeletal Diseases Other Diseases | KLK5 inhibitors | Daiichi Sankyo Co., Ltd. | Daiichi Sankyo Co., Ltd. | Phase 1 | - | - | - | - | - | - | - | - | - | DS-2325 | - | - | detail > | |
| ATR-12 | ATR-12 | Recombinant LBP | Congenital Disorders Skin and Musculoskeletal Diseases Other Diseases | KLK5 inhibitors Bacteria replacements | Azitra, Inc. | Azitra, Inc. | Phase 1 | - | - | - | - | - | - | - | - | - | ATR-12 | - | - | detail > | |
| RO7449135 | RO7449135 | Bispecific antibody | Congenital Disorders Skin and Musculoskeletal Diseases Other Diseases | KLK5 inhibitors KLK7 inhibitors | Genentech, Inc. | Genentech, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | RO7449135 | - | - | detail > | |
| RVB-003 | RVB-003 | Recombinant LBP | Congenital Disorders Skin and Musculoskeletal Diseases Other Diseases | KLK5 inhibitors | ResVita Bio, Inc. | ResVita Bio, Inc. | Preclinical | - | - | - | - | Orphan Drug（United States） | - | - | - | - | RVB-003 | - | - | detail > | |
| TRIV-573 | TRIV-573 | Bispecific antibody | Digestive System Disorders Other Diseases | IL-13 inhibitors KLK5 inhibitors KLK7 inhibitors | Triveni Bio, Inc. | Triveni Bio, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | TRIV-573 | - | - | detail > | |
| Anti-KLK5/KLK7 bispecific antibody(Genentech) | Anti-KLK5/KLK7 bispecific antibody(Genentech) | Biological products | Immune System Diseases Congenital Disorders Skin and Musculoskeletal Diseases Other Diseases | KLK5 inhibitors KLK7 inhibitors | Genentech, Inc. | Genentech, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | Anti-KLK5/KLK7 bispecific antibody(Genentech) | - | - | detail > | |
| GSK951 | GSK951 | Small molecule drug | Congenital Disorders Skin and Musculoskeletal Diseases Other Diseases | KLK5 inhibitors | GSK Plc | GSK Plc | Preclinical | - | - | - | - | - | - | - | - | - | GSK951 | - | - | detail > | |
| IL322167 | IL322167 | Small molecule drug | Immune System Diseases Infectious Diseases Endocrinology and Metabolic Disease Respiratory Diseases Skin and Musculoskeletal Diseases Urogenital Diseases Other Diseases | - | Dermabio Ltd. | Dermabio Ltd. | Discovery | - | - | - | - | - | - | - | - | - | IL322167 | - | - | detail > |
Total 14 data
1
2
